- Home
- AGMH vs DRMA Comparison
AGMH vs DRMA Comparison
Compare AGMH & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- DRMA
- Stock Information
- Founded
- AGMH 2015
- DRMA 2014
- Country
- AGMH Hong Kong
- DRMA United States
- Employees
- AGMH N/A
- DRMA N/A
- Industry
- AGMH EDP Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- DRMA Health Care
- Exchange
- AGMH Nasdaq
- DRMA Nasdaq
- Market Cap
- AGMH 3.5M
- DRMA 3.5M
- IPO Year
- AGMH 2018
- DRMA 2021
- Fundamental
- Price
- AGMH $1.97
- DRMA $5.48
- Analyst Decision
- AGMH
- DRMA Strong Buy
- Analyst Count
- AGMH 0
- DRMA 1
- Target Price
- AGMH N/A
- DRMA $10.00
- AVG Volume (30 Days)
- AGMH 67.6K
- DRMA 28.3K
- Earning Date
- AGMH 05-13-2025
- DRMA 08-13-2025
- Dividend Yield
- AGMH N/A
- DRMA N/A
- EPS Growth
- AGMH N/A
- DRMA N/A
- EPS
- AGMH 6.43
- DRMA N/A
- Revenue
- AGMH $32,044,575.00
- DRMA N/A
- Revenue This Year
- AGMH N/A
- DRMA N/A
- Revenue Next Year
- AGMH N/A
- DRMA N/A
- P/E Ratio
- AGMH $0.29
- DRMA N/A
- Revenue Growth
- AGMH N/A
- DRMA N/A
- 52 Week Low
- AGMH $1.09
- DRMA $5.09
- 52 Week High
- AGMH $109.50
- DRMA $24.90
- Technical
- Relative Strength Index (RSI)
- AGMH 35.63
- DRMA 37.22
- Support Level
- AGMH $1.94
- DRMA $5.09
- Resistance Level
- AGMH $2.43
- DRMA $6.09
- Average True Range (ATR)
- AGMH 0.17
- DRMA 0.52
- MACD
- AGMH -0.00
- DRMA -0.09
- Stochastic Oscillator
- AGMH 13.21
- DRMA 20.22
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.